Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.64 +0.66%
Revenue Growth %: -4.6%
Financial Fact:
Cash dividends paid per common share (in dollars per share): 0.3
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -4.6%
Financial Fact:
Cash dividends paid per common share (in dollars per share): 0.3
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q3 EPS of $0.87, $0.21 better than the analyst estimate of $0.66. Revenue for the quarter came in at $16.7 billion versus the consensus estimate of $16.8 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $3.00-$3.15, versus the consensus of $3.04. Pfizer sees FY2025 revenue of $61-64 billion, versus the consensus of $62.8 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nucor projects Q3 2026 earnings above prior year, below estimates
- Treace reports 5-year Lapiplasty study data at AOFAS meeting
- Nomad Power Solutions files SEC disclosure after merger completion
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
